Immune evaluation with skin tests in prostatic carcinoma.
By intradermal injection of 3 recall antigens, nonspecific secondary cell immunity was studied in 61 patients with prostatic carcinomas. Immune competence is lower in patients with metastatic disease. Skin tests have a short-term prognostical value.